Global Biosimilar Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Biosimilar Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine.
A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilar drug is officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.
Biosimilar Drug report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Biosimilar Drug market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Ankylosing Spondylitis and Tumor are the major drivers for the industry.
In China, Biosimilar Drug key players include CP Guojian Pharma, Biotech Pharma, Celgen Pharma, etc. Global top three manufacturers hold a share over 70%.
East China is the largest market, with a share over 70%, followed by North China, with a share about 15 percent.
In terms of product, Tablets is the largest segment, with a share over 65%. And in terms of application, the largest application is Ankylosing Spondylitis, followed by Rheumatoid Arthrtis, Tumor, Cardiovascular, etc.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Biosimilar Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
CP Guojian Pharma
Biotech Pharma
Celgen Pharma
Henlius
Amgen
Eli Lilly
Sandoz
Changchun High Tech
Innovent
Segment by Type
Injection
Tablets
Other Types
Ankylosing Spondylitis
Tumor
Rheumatoid Arthrtis
Cardiovascular
Other Application
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Biosimilar Drug market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Biosimilar Drug, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Biosimilar Drug industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Biosimilar Drug in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Biosimilar Drug introduction, etc. Biosimilar Drug Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Biosimilar Drug market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
A biosimilar in this report is a biologic medical product which is copy of an original product that is manufactured by a different company. Biosimilar drug is officially approved versions of original “innovator” products, and can be manufactured when the original product's patent expires.
Biosimilar Drug report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Biosimilar Drug market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Ankylosing Spondylitis and Tumor are the major drivers for the industry.
In China, Biosimilar Drug key players include CP Guojian Pharma, Biotech Pharma, Celgen Pharma, etc. Global top three manufacturers hold a share over 70%.
East China is the largest market, with a share over 70%, followed by North China, with a share about 15 percent.
In terms of product, Tablets is the largest segment, with a share over 65%. And in terms of application, the largest application is Ankylosing Spondylitis, followed by Rheumatoid Arthrtis, Tumor, Cardiovascular, etc.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Biosimilar Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
CP Guojian Pharma
Biotech Pharma
Celgen Pharma
Henlius
Amgen
Eli Lilly
Sandoz
Changchun High Tech
Innovent
Segment by Type
Injection
Tablets
Other Types
Segment by Application
Ankylosing Spondylitis
Tumor
Rheumatoid Arthrtis
Cardiovascular
Other Application
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Biosimilar Drug market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Biosimilar Drug, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Biosimilar Drug industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Biosimilar Drug in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Biosimilar Drug introduction, etc. Biosimilar Drug Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Biosimilar Drug market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.